Perceptive Advisors LLC Continues to Hold Stake in ADMA Biologics Inc (ADMA)

Perceptive Advisors LLC maintained its stake in ADMA Biologics Inc (NASDAQ:ADMA) during the first quarter, Holdings Channel reports. The firm owned 721,102 shares of the biotechnology company’s stock at the end of the first quarter. Perceptive Advisors LLC owned about 0.06% of ADMA Biologics worth $3,519,000 at the end of the most recent reporting period.

Separately, Vanguard Group Inc. raised its position in shares of ADMA Biologics by 3.2% in the first quarter. Vanguard Group Inc. now owns 150,028 shares of the biotechnology company’s stock worth $732,000 after buying an additional 4,634 shares in the last quarter. Hedge funds and other institutional investors own 71.71% of the company’s stock.

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics Inc (ADMA) traded down 4.245% during mid-day trading on Friday, reaching $3.045. The company’s stock had a trading volume of 91,553 shares. ADMA Biologics Inc has a 1-year low of $2.96 and a 1-year high of $8.00. The company’s market capitalization is $39.24 million. The firm has a 50 day moving average price of $3.92 and a 200-day moving average price of $4.69.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, May 12th. The biotechnology company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.23. ADMA Biologics had a negative return on equity of 6,405.90% and a negative net margin of 191.99%. The firm had revenue of $2.63 million during the quarter, compared to the consensus estimate of $3.35 million. On average, equities analysts predict that ADMA Biologics Inc will post ($1.28) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Perceptive Advisors LLC Continues to Hold Stake in ADMA Biologics Inc (ADMA)” was originally posted by Mideast Time and is the sole property of of Mideast Time. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at

A number of research analysts recently weighed in on the company. ValuEngine lowered ADMA Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Maxim Group set a $13.00 price objective on ADMA Biologics and gave the stock a “buy” rating in a report on Wednesday, June 7th.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ADMA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding ADMA? Visit to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA).

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.